APEPTICO Forschung und Entwicklung GmbH

Founded

2008

Staff

6

Organization type

RDM biotech/pharma

Region

Vienna

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals.

R&D:APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening pulmonary diseases, including edematous respiratory failure, acute lung injury, ARDS, Influenza, pneumonia, primary graft dysfunction, ischemia reperfusion injury and high altitude pulmonary edema. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.

Production:APEPTICO’s family of Solnatide peptides are synthetic peptides which corresponds to structural motifs of human proteins. All AP301 peptides activate lung fluid clearance and protect both endothelial and epithelial lung tissue from microbial toxin- and reactive oxygen species-induced hyper-permeability. The peptides are being developed by APEPTICO in various pulmonary indications. APEPTICO's Solnatide peptides are subject to phase III clinical studies.

Services:APEPTICO’s database PEPBASE(TM) combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on the biological and structural assessment of discrete domains and structural elements of well-characterised proteins and biopharmaceuticals by PEPBASE(TM), a proposal for a peptide structure is assigned by semi-rational technology, combining molecular visualization, protein-protein interaction calculations, in-silico stability analysis, followed by computerised energy and toxicology evaluations.